NCT06703021 - A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

ObesityOverweightChronic Weight Management

Interventions

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

Trial Locations (10)

29405

ACCESS II Research Site, North Charleston

46383

ACCESS II Research Site, Valparaiso

50265

ACCESS II Research Site, West Des Moines

75042

ACCESS II Research Site, Dallas

78240

ACCESS II Research Site, San Antonio

84088

ACCESS II Research Site, West Jordan

91206

ACCESS II Research Site, Glendale

91763

ACCESS II Research Site, Montclair

97504

ACCESS II Research Site, Medford

02818

ACCESS II Research Site, East Greenwich

All Listed Sponsors

lead

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

INDUSTRY